CULVER CITY, Calif. -- (Business Wire)
NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system by using the natural killer cell to treat cancer,
infectious diseases and inflammatory diseases, announced today the
pricing of its initial public offering of 8,288,000 shares of its common
stock at a price to the public of $25.00 per share. All of the shares
are being offered by NantKwest. The shares are expected to begin trading
on The Nasdaq Global Select Market on July 28, 2015, under the symbol
"NK." In addition, NantKwest has granted the underwriters a 30-day
option to purchase up to an additional 1,243,200 shares of its common
stock. Concurrently with the initial public offering, NantKwest is also
selling 680,000 shares of its common stock in a separate private
placement to Celgene Corporation, an existing stockholder, at the
initial public offering price of $25.00 per share.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and
Piper Jaffray are acting as joint book-running managers for the
offering, and MLV & Co. LLC is acting as co-manager.
Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective on July
27, 2015. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
The offering is being made only by means of a prospectus. A copy of the
final prospectus related to the offering may be obtained, when
available, from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038,
Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by email at prospectus@citi.com,
or by telephone at (800) 831-9146; Jefferies LLC, Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com;
or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, Suite 800, Minneapolis, MN 55402, or by email at prospectus@pjc.com,
or by telephone at (800) 747-3924.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150727006420/en/
Contacts:
NantKwest
Jen Hodson, 562-397-3639
jen@nantworks.com
Source: NantKwest, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.